Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma

Standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapies such as axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are associated with multisystem toxicities. There is limited information available about cardiovascular (CV) events associated with SOC axi-cel or tisa-ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiner, Raphael E., Banchs, Jose, Koutroumpakis, Efstratios, Becnel, Melody, Gutierrez, Cristina, Strati, Paolo, Pinnix, Chelsea C., Feng, Lei, Rondon, Gabriela, Claussen, Catherine, Palaskas, Nicolas, Karimzad, Kaveh, Ahmed, Sairah, Neelapu, Sattva S., Shpall, Elizabeth, Wang, Michael, Vega, Francisco, Westin, Jason, Nastoupil, Loretta J., Deswal, Anita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Cell Therapy and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244830/
https://www.ncbi.nlm.nih.gov/pubmed/34758610
http://dx.doi.org/10.3324/haematol.2021.280009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244830/
https://www.ncbi.nlm.nih.gov/pubmed/34758610
http://dx.doi.org/10.3324/haematol.2021.280009

Ejemplares similares